Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.

Appendix 1
Sample Information to Be Provided to Patients at Discharge, With a Copy Retained on the Patient Chart


Discharge instructions for the health-care provider of: ____________________________
Patient Name
This patient was discharged from ____ Outpatient Clinic of _______________________
____ Emergency Department Institution
____ Hospital
On Date: _______/_____/_____
Month / Day / Year
This patient received pre-discharge administration of:
_____ Tetanus toxoid–containing vaccine
____ DTaP Manufacturer____________ Lot # _____________
____ Tdap Manufacturer____________ Lot # _____________
____ Td Manufacturer____________ Lot # _____________
____ TT Manufacturer____________ Lot # _____________
_____ Tetanus Immune Globulin (TIG)
____ Dose Manufacturer____________ Lot # _____________
_____ Hepatitis B vaccine
Manufacturer____________ Lot # _____________
Product: _____________________ Dose: ________________________
This patient will need further evaluation regarding whether administration of a vaccine or completion of an immunization
series is needed.
Evaluate need for immunization series completion:
_____Tetanus
_____Hepatitis B
_____Other:___________________________
Assess need for evaluation of seroconversion to:
_____Hepatitis C infection
• Baseline testing for anti-HCV and alanine aminotransferase (ALT) within 7–14 days of the exposure
• Follow-up testing for anti-HCV and ALT 4–6 months after exposure to assess seroconversion
• HCV RNA test at 4–6 weeks if earlier diagnosis of HCV infection is desired
• Confirm positive anti-HCV with low signal-to-cutoff results using a more specific supplemental assay before
communicating results to patient
_____HIV infection
Follow up on the following tests collected during the acute care visit:
_______AST/ALT
_______Hepatitis C virus serology
_______HIV serology
Antibiotic or other antimicrobial given:
Specific discharge instructions that need further medical evaluation:
Wound care instructions:
Other:
 

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.


References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Date last reviewed: 7/9/2008

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services